Recombinant Human IL-8/CXCL8 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01892P-100UG

Human IL-8 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human IL-8/CXCL8 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01892P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human IL-8/CXCL8 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ser28-Ser99. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P10145 |
Target Symbol | IL-8/CXCL8 |
Synonyms | Interleukin-8; IL-8; GCP-1; MDNCF; MONAP; NAP-1; GCP/IL-8 protein IV; IL8/NAP1 form I; CXCL8; LECT; LUCT; LYNAP; NAF |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Ser28-Ser99 |
Mol. Weight | The protein has a predicted MW of 9.5 kDa. Due to glycosylation, the protein migrates to 11-13 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human IL-8, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-IL-8 Antibody, hFc Tag with the EC50 of 12.5ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms. |